Rivastigmine for Alzheimer's disease
To browse Podcasts by topic, please visit the new Cochrane Summaries site here
The use of cholinesterase inhibitors in people with Alzheimer's disease has long been a focus of interest and concern. In this podcast, Jacqueline Birks, a researcher from Oxford, England, reports the results of an updated systematic review studying the benefits and harms of one of these agents, rivastigmine, including a novel mode of percutaneous administration.
This Podcast also available in: French
Play Now!
Download [mp3]
| Read Review
Updated on: June 20, 2011, 14:39
Copyright © The Cochrane Collaboration
Comments for improvement or correction are welcome.
Email: web@cochrane.org



